This is a website for healthcare professionals.
Publications
Cell-Bound Complement Activation Products (CB-CAPs)
Petri M, et al. Lupus Science & Medicine. 2019. Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE.
Merrill J, et al. Lupus Science & Medicine. 2018. Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE.
Ramsey-Goldman R, et al. Lupus Science & Medicine. 2017. Cell-bound complement activation products in SLE.
Buyon J, et al. Lupus Science & Medicine. 2016 – Reduction in EC4d and anti-C1q antibodies associate with clinical improvement in SLE.
Wallace D, et al. Lupus Science & Medicine. 2016. Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products.
Mossell J, et al. Open Rheumatology Journal. November 2016. The AVISE Lupus Test and Cell-bound Complement Activation Products Aid the Diagnosis of Systemic Lupus Erythematosus.
Mosca M, et al. Arthritis & Rheumatology. 2019. How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria
Putterman C, et al. Lupus Science & Medicine. 2014. Cell bound complement activation products in systemic lupus erythematosus.
Methotrexate polyglutamates (MTXPGs)
Brady K, et al. American Association for Clinical Chemistry. 2019. Transition of Methotrexate Polyglutamate Drug Monitoring Assay from Venipuncture to Capillary Blood-Based Collection Method in Rheumatic Diseases
Dervieux T, et al. Annals of the Rheumatic Diseases. 2018. Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept.
Dervieux T, et al. Annals of the Rheumatic Diseases. 2012. Methotrexate polyglutamation in relation to infliximab pharmacokinetics in rheumatoid arthritis.
Dervieux T, et al. Annals of the Rheumatic Diseases. 2005. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study.
Dervieux T, et al. Arthritis & Rheumatism. 2006. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis.
Kremer J. Arthritis & Rheumatism. 2004. Toward a better understanding of methotrexate.
Dervieux T, et al. Clinical Chemistry. 2003. HPLC Determination of Erythrocyte Methotrexate Polyglutamates after Low-Dose Methotrexate Therapy in Patients with Rheumatoid Arthritis.
Anti-Carbamylated Protein Antibodies (Anti-CarP)
Weinstein A, et al. The Journal of Rheumatology. 2019. Reevaluating Serologic Markers of Poor Prognostic Factors in Rheumatoid Arthritis.
Shi J, et al. PNAS. 2011. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage.
Abstracts
An Evaluation of the Economic Impact of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis Using Complement C4D Activation Products in a Multivariate Assay.
ACR Chicago 2018. Genetic Polymorphism in Dihydrofolate Reductase Impacts Methotrexate Polyglutamation in Adult Rheumatoid Arthritis
ACR Chicago 2018. Capillary Blood Based Methotrexate Polyglutamate Assay for Monitoring Low Dose Methotrexate Therapy in Rheumatic Diseases
ACR Chicago 2018 • Complement C4d Split Products in Combination With lupus Anticoagulant and Low Complement Associate With Thrombosis in Systemic lupus erythematosus
ACR San Diego 2017. Abnormalities in Complement System are Related to Disease Severity Index in Systemic lupus erythematosus
ACR Chicago 2018 • Diagnostic Performances of Antibodies Against Carbamylated Proteins in U.S. Rheumatoid Arthritis and Other Autoimmune Rheumatic Diseases
ACR San Diego 2017. Complement Activation in Peripheral Blood in Relation to lupus, Antiphospholipid and Rheumatoid Arthritis Autoantibodies: Insights From Clinical Laboratory Evaluations
ACR San Diego 2017. A Panel of lupus Biomarkers for the Monitoring of systemic lupus erythematosus: Performance Characteristics in Distinct SLE Cohorts
ACR San Diego 2017. Cell bound Complement Activation Products Distinguish systemic lupus erythematosus From Other Diseases Among Patients With High Antinuclear Antibody Titers and Normal Complement.
ACR San Diego 2017. Abnormalities in Complement System are Related to Disease Severity Index in Systemic lupus erythematosus
ACR Chicago 2018 • Diagnostic Performances of Antibodies Against Carbamylated Proteins in U.S. Rheumatoid Arthritis and Other Autoimmune Rheumatic Diseases
ACR San Diego 2017. Complement Activation in Peripheral Blood in Relation to lupus, Antiphospholipid and Rheumatoid Arthritis Autoantibodies: Insights From Clinical Laboratory Evaluations
ACR San Diego 2017. A Panel of lupus Biomarkers for the Monitoring of systemic lupus erythematosus: Performance Characteristics in Distinct SLE Cohorts
ACR San Diego 2017. Cell bound Complement Activation Products Distinguish systemic lupus erythematosus From Other Diseases Among Patients With High Antinuclear Antibody Titers and Normal Complement.